Biotech company Aqilion AB (publ) announced on Thursday that it has sold its entire stake in Oncorena Holding AB to existing shareholders.

The divestment aligns with Aqilion's strategy to prioritize internal pipeline programs focused on chronic inflammation.

Aqilion played a key role in establishing Oncorena and has provided long-term support. CEO Sarah Fredriksson states that transferring ownership to specialized life science investors benefits Oncorena's continued development.

Oncorena is advancing a novel treatment for advanced kidney cancer. Existing investors will maintain active support for the company's progress.